期刊文献+

MMP和TIMP-1在幽门螺旋杆菌感染胃溃疡和非甾体类抗炎药相关胃溃疡中的表达 被引量:7

下载PDF
导出
摘要 目的观察在幽门螺旋杆菌感染和非甾体抗炎药相关性溃疡中基质金属蛋白酶(MMPs)和基质金属蛋白酶组织抑制因子(TIMP-1)的表达。方法 93例胃溃疡患者(感染幽门螺旋杆菌32例;非甾体类抗炎药相关30例;两个因素相结合31例),健康对照组30例。取患者血液用酶联免疫法测定血清MMP-3,-7,-9和TIMP-1表达。结果胃溃疡患者中MMP-3,-7和-9和TIMP-1的表达明显高于健康组(P<0.05)。幽门螺旋杆菌感染的胃溃疡患者比非甾体类抗炎药相关组有更高MMP-7,MMP-9,TIMP-1表达(P<0.05)。幽门螺旋杆菌感染和非甾体类抗炎药相关双因素组MMP-7和MMP-9的强度与非甾体类抗炎药相关组表达类似,但比幽门螺旋杆菌感染组低(P<0.05)。结论幽门螺旋杆菌感染的胃溃疡与非甾体类抗炎药相关溃疡表达MMP-7,MMP-9,TIMP-1较高。幽门螺旋杆菌感染和非甾体类抗炎药相关双因素组MMP-7和MMP-9的强度与非甾体类抗炎药相关胃溃疡患者相似。
作者 旷枫
出处 《临床和实验医学杂志》 2013年第20期1677-1678,共2页 Journal of Clinical and Experimental Medicine
  • 相关文献

参考文献11

  • 1Arkkila PE, Seppala K, Kosunen TU, et al. Eradication of Helicobact- er pylori improves the healing rate and reduces the relapse rate of non- bleeding ulcers in patients with bleeding peptic ulcer[ J ]. Am J Gastro- enterol, 2003,98(10) :2149 -2156.
  • 2Tarnawski AS. Cellular and molecular mechanisms of gastrointestinal ul- cer healing [ J ]. Dig Dis Sci, 2005,50 ( 1 ) :24 - 33.
  • 3Bodger K, Ahmed S, Pazmany L, et al. Altered gastric corpus expres- sion of tissue inhibitors of metalloproteinases in human and murine Heli- cobacter infection[ J]. J Clin Pathol, 2008,61 ( 1 ) :72 - 78.
  • 4Tomita M, Ando T, Minami M, et al. Potential role for matrix metallo- proteinase - 3 in gastric ulcer healing [ J ]. Digestion, 2009,79 ( 1 ) :23 - 29.
  • 5消化性溃疡病诊断与治疗规范建议(2008,黄山)[J].中华消化杂志,2008,28(7):447-450. 被引量:248
  • 6顾晓萌,赵幼安.幽门螺杆菌感染的诊断方法[J].临床内科杂志,2003,20(2):111-112. 被引量:5
  • 7Pender SL, MacDonald TY. Matrix metalloproteinases and the gut - new roles for old enzymes [ J ]. Curt Opin Pharmacol, 2004,4 ( 6 ) : 546 - 550.
  • 8Mori N, Sato H, Hayashibara T, et al. I-Ielicobacter pylori induces ma- trix metalloproteinase - 9 through activation of nuclear factor kappaB [ J]. Gastroenterology, 2003,124 (4) :983 - 992.
  • 9Takada Y, Bhardwaj A, Potdar P, et al. Nonsteroidal anti - inflamma- tory agents differ in their ability to suppress NF - kappaB activation, in- hibition ofexpression of cyelooxygenase - 2 and eyelin D1, and abroga- tion of tumor cell proliferation [ J ]. Oneogene, 2004,23 ( 57 ) : 9247 - 9258.
  • 10Mori N, Sato H, Hayashibara T, et al. Helicobacter pylori induces ma- trix metaUoproteinase - 9 through activation of nuclear factor kappaB [ J 1. Gastroenterology, 2003,124 (4) :983 - 992.

二级参考文献23

  • 1无,许国铭(整理),邹多武(整理).中国消化性溃疡治疗现状调查报告[J].中华消化杂志,2007,27(2):114-117. 被引量:116
  • 2Konturek SJ. Konlurek PC, Konturek JW, et al. Helicobacter pylori and its involvement in gastritis and peptic ulcer formation.J PhysiolPharmacol, 2006,57 (Suppl 3): 29-50.
  • 3Atherton JC. The pathugenesis of Helicobacter pylori induced gastro duodenal diseases. Annu Rev Pathol,2006,1:63-96.
  • 4Hamajima N. Persistent Helieobacter pylori infection and genetic polymorphisms of the host. Nagoya J Med Sci, 2003, 66: 103-117.
  • 5Dincer D, Duman A, Dikici H, et al. NSAID-related upper gastrointestinal bleeding: are risk factors considered during prophylaxis? Int J Clin Pract,2006,60 : 546-548.
  • 6Zapata Colindres JC, Zepeda Gomez S, Montano Loza A, et al. The association of Helicobacter pylori infection and nonsteroidal anti inflammatory drugs in peptic ulcer disease. Can J Gastroenterol, 2006, 20: 277-280.
  • 7Metz DC, Sostek MB, Ruszniewski P, et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol, 2007, 102:2648-2654.
  • 8Egan BJ, Katicic M, O'Connor HJ, et al. Treatment of Helicobacter pylori. Helicobacter, 2007, 12:31-37.
  • 9Zullo A, Rinaldi V, Winn S, et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther, 2000. 14: 715-718.
  • 10Tanaka A, Araki H, Hase S, et al. Up regulation of COX-2 by inhibition of COX 1 in the rat: a key NSAID-induced gastric injury. Aliment Pharmacol Ther, 2002, 16(Supple) :90-101.

共引文献251

同被引文献58

引证文献7

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部